Audax Private Equity to Acquire Avantor’s Clinical Services Division
Audax Private Equity (“Audax”) announced today that it has entered into a definitive agreement to acquire the Clinical Services business of Avantor, Inc. (NYSE: AVTR) (“Clinical Services” or “the Company”).…
Agendia Ottiene la Certificazione CE-IVDR per i Test MammaPrint® e BluePrint® sul Cancro al Seno
Oggi, Agendia ha annunciato di aver ricevuto la certificazione dell’Unione Europea (UE) In vitro Diagnostic Medical Device Regulation (IVDR) per tre dei suoi prodotti: MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray…
Scholar Rock Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases influenced by protein growth factors, today announced…
China Approves Enhertu for Treated HER2+ Advanced Gastric Cancer
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have…
Sarepta Therapeutics Q2 2024 Financial Results and Updates
Sarepta Therapeutics, a leader in precision genetic medicine for rare diseases, has announced its financial results for the second quarter of 2024. “This quarter marks a groundbreaking milestone in Duchenne…
Legend Biotech Announces Q2 2024 Financial Results and Key Developments
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced its unaudited financial results and notable corporate developments for the second quarter of 2024. CEO Statement Ying…
Hansoh Pharma and Lupeng Pharma Reveal Licensing Deal for LP-168
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), a leading innovation-driven pharmaceutical company in China, and Guangzhou Lupeng Pharmaceutical Co., Ltd. (Lupeng Pharma), which specializes in treatments for malignant tumors…
Bio-Techne Reports Fiscal Q4 2024 Financial Results
Bio-Techne’s fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. For the full year, organic revenue rose by 1% (2% reported) to $1.2 billion. GAAP earnings per…
WuXi Biologics and Medigene Team Up for TCR-Guided T Cell Engager Research
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Medigene AG (FSE: MDG1, Prime Standard) have announced a three-year strategic partnership. The collaboration aims to design…
Royalty Pharma Announces Second Quarter 2024 Financial Results
Royalty Pharma today released its financial results for the second quarter of 2024 and announced an increase in its full-year guidance for Portfolio Receipts. We achieved double-digit growth in Portfolio…
Takeda Gets EC Approval for ADZYNMA®: First Recombinant ADAMTS13 Therapy for cTTP
Today, the European Commission (EC) approved ADZYNMA®▼ (recombinant ADAMTS13) for treating ADAMTS13 deficiency in both children and adults with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is now the first and…
Vertex Secures CASGEVY™ Reimbursement for Beta Thalassemia in England
Vertex Announces Reimbursement Agreement with NHS England for CASGEVY™ Vertex has announced a new reimbursement agreement with NHS England, effective immediately, allowing eligible patients with transfusion-dependent beta thalassemia (TDT) to…